Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
UNIVERSITE COTE D'AZUR is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units. This distribution shows that the university's biotech research is being reviewed by different specialized sections of the patent office. The separation into different units suggests that the technologies being patented are distinct enough to require different technical oversight.
The busiest examiner is GONZALEZ, LUISALBERTO, who has 1 busiest_examiner_pending action. With 2 pending office actions total, the workload is shared between the two examiners. The involvement of 2 distinct art units indicates that the patent office has assigned these applications to different technical groups within the biotechnology and pharmaceutical sector. For the legal team, this means managing two separate prosecution tracks, each with its own examiner and art unit standards. This structure requires a focus on the specific requirements of each 1 distinct art unit involved in the university's current patenting efforts.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GONZALEZ, LUISALBERTO | 1 | 59.7% | +46.3% |
| SIMMONS, CHRIS E | 1 | 34.2% | +19.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17603997 | METHODS AND COMPOSITIONS FOR TREATMENT OF NLRP3 INFLAMMASOME MEDIATED IL-1BETA DEPENDENT DISORDERS | SIMMONS, CHRIS E | 56d |
| 18718519 | METHODS AND COMPOSITIONS FOR TREATING MELANOMA | GONZALEZ, LUISALBERTO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17603997 | METHODS AND COMPOSITIONS FOR TREATMENT OF NLRP3 INFLAMMASOME MEDIATED IL-1BETA DEPENDENT DISORDERS | SIMMONS, CHRIS E | 56d |
| 18718519 | METHODS AND COMPOSITIONS FOR TREATING MELANOMA | GONZALEZ, LUISALBERTO | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18718519 | METHODS AND COMPOSITIONS FOR TREATING MELANOMA | GONZALEZ, LUISALBERTO | 1624 | §102§103 | Non-Final OA | — | Pending | Jun 11, 2024 |
| 17603997 | METHODS AND COMPOSITIONS FOR TREATMENT OF NLRP3 INFLAMMASOME MEDIATED IL-1BETA DEPENDENT DISORDERS | SIMMONS, CHRIS E | 1622 | §103§112 | Final Rejection | 56d | Pending | Oct 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITE COTE D'AZUR has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Luisalberto Gonzalez has the most, with 1 of UNIVERSITE COTE D'AZUR's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
